Filing Details

Accession Number:
0001415889-24-013654
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-05-17 21:56:19
Reporting Period:
2024-05-15
Accepted Time:
2024-05-17 21:56:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1656634 Gritstone Bio Inc. GRTS Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1754470 Matthew Hawryluk C/O Gritstone Bio, Inc.
5959 Horton Street, Suite 300
Emeryville CA 94608
Evp, Chief Business Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-05-15 19,149 $0.00 323,190 No 4 A Direct
Common Stock Disposition 2024-05-16 9,259 $0.75 313,931 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2024-05-15 180,000 $0.00 180,000 $0.75
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
180,000 2034-05-14 No 4 A Direct
Footnotes
  1. Represents Performance Stock Units ("PSUs") granted on March 22, 2024 that were earned by the Reporting Person as a result of the achievement of certain performance criteria as certified by the Issuer's Board of Directors on May 15, 2024. The PSUs vest over one year; 1/2 vested on May 15, 2024, and thereafter the remaining 1/2 will vest on May 15, 2025, subject to the continuing service of the Reporting Person on such vesting date. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock.
  2. Includes 273,719 Restricted Stock Units ("RSUs") and PSUs which are subject to vesting.
  3. The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of PSUs.
  4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.735 to $0.7616 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The option vests as to 1/2 of the total grant on September 30, 2024, with the remainder of grant vesting on September 30, 2025, subject to the continued service of the Reporting Person on each vesting date.